Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Randox Laboratories Ltd.. (11/9/18). "Press Release: Randox Cerebral Arrays on the Evidence Series Immunoanalysers".

Organisation Organisation Randox Laboratories Ltd.
  Group Randox (Group)
Products Product Evidence immunoanalyser (product series)
  Product 2 Biochip Array Technology (Randox)
     


The Evidence is the world’s first protein Biochip Array Technology Analyser (BAT). The awarding winning Biochip Array Technology is a multi-analyte testing platform allowing the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

The Evidence is a fully automated immunoanalyser which is renowned for higher standards of quality, efficiency and reliability. It is tailored and more suitable in a wide range of settings including hospital laboratories, clinical laboratories, private and public research applications, veterinary laboratories, forensic and clinical toxicology and pharmaceutical applications.

There are many key features for The Evidence, including the ability to carry out multiplex testing which will allow multiple tests to be carried out from a single patient sample as a result. It reduces the amount of labour spent on the individual tests and therefore saves money and time. The analyser is more suitable for larger laboratories with a throughput of >1500 tests per hour with a fully automated system maximising the walk away time – allowing staff to devote their time to other important tasks.

The multi-analyte barcoded controls and calibrators ensure security, accuracy and reliable laboratory testing. They also allow for full traceability making the overall experience easier. It offers a wide-ranging and diverse test menu which offer more tests than other sole suppliers and this will benefit many research areas including immunology, metabolic, cardiovascular and oncology.

Neurological conditions can affect young and old people and result from damage to the brain, spine or nerves which is triggered by an illness or an injury1. Up to 1 billion people (one in six of the world’s population suffer from neurological disorders from Alzheimer and Parkinson disease, strokes, multiple sclerosis and epilepsy 2. In England the number of deaths from neurological disorders have rose by 39% over the past 13 years3.

Randox offers two Cerebral Arrays which have been designed for the simultaneous measurement of analytes associated with nervous system dysfunctions such as Alzheimer’s disease and multiple sclerosis. The Arrays can measure up to five biomarkers simultaneously. They are suitable for human serum, plasma and cerebrospinal fluid (CSF) samples. Additionally, it offers excellent sensitivity, precision and recovery as well as analytical performance.

For more information on our Evidence Series or Cerebral range of Assays, contact us at EvidenceSeries@randox.com

http://www.neural.org.uk/living-with-a-neurological-condition/what-is-a-neurological-condition
https://news.un.org/en/story/2007/02/210312-nearly-1-6-worlds-population-suffer-neurological-disorders-un-report
https://www.bmj.com/content/360/bmj.k1278

   
Record changed: 2018-11-15

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Randox (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top